Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Avelumab by Merck for Non-Small Cell Lung Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Avelumab by Merck for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to...
Avelumab by Merck for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial...
Avelumab by Merck for Endometrial Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Ureter Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Ureter Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Urethral Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Urethral Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Small-Cell Lung Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...
Avelumab by Merck for Ovarian Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Natural Killer Cell Lymphomas: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData,...
Avelumab by Merck for Gastrointestinal Stromal Tumor (GIST): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According to GlobalData,...
Avelumab by Merck for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Avelumab by Merck for Angiosarcoma: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II drugs...
Avelumab by Merck for Cervical Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Avelumab by Merck for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...
Avelumab by Merck for Small-Cell Lung Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...
Avelumab by Merck for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData,...